Cell adhesion and extracellular matrix proteins

• US 20070276126A1
• Filed: 08/12/2003
• Published: 11/29/2007
• Est. Priority Date: 08/13/2002
• Status: Abandoned Application

• Current Assignee: Incyte Corporation
• Original Assignee: Incyte Corporation
• Inventors: Chien, David, Richardson, Thomas, Jiang, Xin, Wang, Jonathan, Jackson, Alan, Khare, Reena, Jin, Pei, Swarnakar, Anita, Kable, Amy, Ramkumar, Jayalaxmi, Yang, Yonghong, Marquis, Joseph, Tran, Uyen, Chawla, Narinder, Elliott, Vicki, Emerling, Brooke, Becha, Shanya, Hafalia, April, Lee, Soo, Blake, Julie
• Application Number:
  US10/524,355
• Publication Number:
  US 20070276126A1
• Time in Patent Office: Days
• US Class Current: 530/350
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Various embodiments of the invention provide human cell adhesion and extracellular matrix proteins (CADECM) and polynucleotides which identify and encode CADECM. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CADECM.

Claims

1-139. -139. (canceled)

140. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence of SEQ ID NO;

11;

(b) a biologically active fragment of the polypeptide of (a); and

(c) an immunogenic fragment of the polypeptide of (a).

141. An isolated polypeptide of claim 140 consisting of the polypeptide of (a).

142. An isolated polypeptide of claim 140 consisting of a biologically active fragment of the polypeptide of (a).

143. An isolated polypeptide of claim 140 consisting of an immunogenic fragment of the polypeptide of (a).

144. An isolated polypeptide of claim 140 encoded by a polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO;

53;

(b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO;

53;

(c) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO;

53 that specifically identifies SEQ ID NO;

53;

(d) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (a), (b), or (c);

(e) an RNA equivalent of the polynucleotide of (a), (b), (c) or (d);

(f) a polynucleotide of (a), (b) or (c) further comprising a promoter sequence operably linked to said polynucleotide of (a), (b) or (c).

145. An isolated polypeptide of claim 140 produced recombinantly.

146. An isolated polypeptide of claim 144 produced by culturing a cell transformed with a polynucleotide of (d) under conditions suitable for expression of the polypeptide, and recovering the polypeptide so expressed.

147. An isolated antibody that specifically binds to a polypeptide of claim 140.

148. An isolated antibody of claim 147, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab′

)₂ fragment, and a humanized antibody.

149. An isolated antibody of claim 147, wherein said antibody is selected by screening a recombinant immunoglobulin library.

150. An isolated antibody of claim 148, wherein said antibody is selected by screening a Fab expression library.

151. An isolated antibody that specifically binds to a polypeptide of claim 144.

152. An isolated antibody of claim 151, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab′

)₂ fragment, and a humanized antibody.

153. An isolated antibody of claim 151, wherein said antibody is selected by screening a recombinant immunoglobulin library.

154. An isolated antibody of claim 151, wherein said antibody is selected by screening a Fab expression library.

155. A method of detecting a polypeptide of interest in a sample, comprising:

(a) incubating the sample with an antibody that specifically binds to a polypeptide of claim 140 under conditions suitable for binding of the antibody to the polypeptide of interest if present in the sample; and

(b) detecting biding of the polypeptide of interest to the antibody, wherein binding indicates the presence or amount of the polypeptide of interest in the sample.

156. A method of claim 155, wherein the sample is a body fluid sample from a human.

157. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO;

53;

(b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO;

53;

(c) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO;

53 that specifically identifies SEQ ID NO;

53.

(d) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (a), (b), or (c);

(e) an RNA equivalent of the polynucleotide of (a), (b), (c) or (d);

(f) a polynucleotide of (a), (b) or (c) further comprising a promoter sequence operably linked to said polynucleotide of (a), (b) or (c).